Eliminating Ambiguous Treatment Effects Using Estimands
- PMID: 36790803
- PMCID: PMC10236519
- DOI: 10.1093/aje/kwad036
Eliminating Ambiguous Treatment Effects Using Estimands
Abstract
Most reported treatment effects in medical research studies are ambiguously defined, which can lead to misinterpretation of study results. This is because most authors do not attempt to describe what the treatment effect represents, and instead require readers to deduce this based on the reported statistical methods. However, this approach is challenging, because many methods provide counterintuitive results. For example, some methods include data from all patients, yet the resulting treatment effect applies only to a subset of patients, whereas other methods will exclude certain patients while results will apply to everyone. Additionally, some analyses provide estimates pertaining to hypothetical settings in which patients never die or discontinue treatment. Herein we introduce estimands as a solution to the aforementioned problem. An estimand is a clear description of what the treatment effect represents, thus saving readers the necessity of trying to infer this from study methods and potentially getting it wrong. We provide examples of how estimands can remove ambiguity from reported treatment effects and describe their current use in practice. The crux of our argument is that readers should not have to infer what investigators are estimating; they should be told explicitly.
Keywords: estimands; estimates; estimators; randomized trials; treatment effects.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
Comment in
-
RE: "ELIMINATING AMBIGUOUS TREATMENT EFFECTS USING ESTIMANDS".Am J Epidemiol. 2023 Jun 2;192(6):1029-1030. doi: 10.1093/aje/kwad070. Am J Epidemiol. 2023. PMID: 36958822 No abstract available.
References
-
- Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543–1552. - PMC - PubMed
-
- Greenberg L, Jairath V, Pearse R, et al. Pre-specification of statistical analysis approaches in published clinical trial protocols was inadequate. J Clin Epidemiol. 2018;101:53–60. - PubMed
